Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| European and Developing Countries Clinical Trials Partnership (EDCTP) | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The ERASE - TB study will be conducted in order to fill a critical unmet need for tuberculosis control. Persons who are in contact with an infectious TB case may become infected themselves. Among those who are infected, most will stay healthy but some will develop TB themselves.
These people would benefit from preventive treatment, which would also stop TB from being spread to other persons.
The problem currently is that it is impossible to determine with certainty who would require preventive treatment, and who will remain healthy. Out of 100 persons exposed to an infectious TB patient, only 2 will go on to have TB according to a study in Vietnam, but there are no good tests available to identify those with a risk for TB disease. Treating 100 persons to prevent 2 cases of TB is not effective, so preventive treatment is not used in adults and adolescents in Tanzania, Mozambique and Zimbabwe, where this study will be conducted, but also in many other settings.
The ERASE - TB project will evaluate a number of newly developed diagnostic tests, to see which of those will be able to predict TB in persons at risk, and therefore steer preventive treatment well.
For this, the investigators will invite 2,100 household contacts (HHC) of infectious TB patients, who are at least 10 years old, into the study. Everyone will be examined initially, and again in regular intervals, for 1.5 to 2 years; and whenever the participants will present with symptoms that could indicate that they develop TB.
At every visit, the investigators will perform an X-ray and take some blood and urine samples to perform new candidate tests. At the first/baseline visit, all household contacts without TB will undergo a spirometry to evaluate their pulmonary function.
If someone is unwell, the investigators will also examine sputum for the presence of TB bacilli. In the end, the investigators will then be able to say who of the persons in the study developed TB, and who remained healthy. From all samples taken at different timepoints, the investigators will then determine which test found TB early, and clearly distinguished between persons developing TB, and persons who would remain healthy .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Household contacts with co-prevalent/incipient TB | Household contacts diagnosed with active TB at baseline/during the study period |
| |
| Household contacts staying healthy | Household contacts without active TB who remain healthy throughout the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| New test candidates | Diagnostic Test | The following new diagnostic tests will be done after the completion of the study with the samples (blood, sputum, urine) and data (digital X-ray) obtained during the study period: CAD4TB / qXR Xpert Ultra® FLOW-TB TAM-TB 4RISK and COR Cepheid 3-gene signature cartridge BioMérieux ISIT TB blood transcription signature assay Multiplex LSHTM in-house host biomarker assay TB Screen biosignature SeroSelect Retrospective testing of participants' samples and data acquired during the study period, differentiated between participants with co-prevalent/incipient TB and participants staying health throughout the trial |
| Measure | Description | Time Frame |
|---|---|---|
| Sensitivity and specificity of new diagnostics to diagnose co-prevalent TB against a clinica/microbiological reference standard case definition | to determine sensitivity and specificity of new diagnostics for diagnosing TB earlier with a special focus on subclinical disease. New diagnostics will be evaluated against a reference standard for classification of presence of, or development of TB disease in a person exposed to a source case; with the following possibilities:
| Co-prevalent TB disease can be diagnosed at Baseline (Month 0) |
| Evaluation of novel diagnostics for detection of developing, minimal TB against a clinica/microbiological reference standard case definition | to evaluate novel diagnostics for detection of developing, minimal TB that would cause infectious disease in the future. For reference standard case classification, see 1. | TB disease can be diagnosed through study completion, up to Month 24 |
| Enhancement of diagnostic performance by simulating testing algorithms coupled with a risk estimate from a mathematical model | to enhance diagnostic performance by simulating testing algorithms coupled with a risk estimate from a mathematical model For reference standard case classification, see 1. | TB disease can be diagnosed through study completion, up to Month 24 |
| Measure | Description | Time Frame |
|---|---|---|
| M.tb infection status as measured by an immunological assay | M.tb infection status as measured by an immunological assay:
| through study completion, up to Month 24 |
| Measure | Description | Time Frame |
|---|---|---|
| To explore elements shaping adoption of new TB detection technologies among asymptomatic members of community (sub-study I) | In-depth qualitative interviews will be conducted to understand how new technologies could support screening and follow-up of household contacts. | August 2021 to February 2022 |
Inclusion Criteria:
TB index case:
Household Contact:
Exclusion Criteria:
Household Contact
Not provided
Not provided
Not provided
TB index cases will be recruited at the primary health care clinics where the patient is receiving TB treatment. Household contacts have substantial recent exposure to the TB index case in the household (defined as sleeping at least 3/7 nights in the same household in the last 4 weeks).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Theodora Mbunda, MD, PhD | National Institute of Medical Research - Mbeya Medical Research Centre | Principal Investigator |
| Denise F Banze, MD | Instituto Nacional de Saúde (INS) | Principal Investigator |
| Junior Mutsvangwa, MD | Biomedical Research & Training Institute (BRTI) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Instituto Nacional de Saúde (INS) Centro de Investigação e Treino em Saúde da Polana Caniço | Maputo | Mozambique | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30021818 | Background | Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, Ma S, Meermeier E, Lewinsohn DM, Sherman DR. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. Clin Microbiol Rev. 2018 Jul 18;31(4):e00021-18. doi: 10.1128/CMR.00021-18. Print 2018 Oct. | |
| 29342390 | Background |
| Label | URL |
|---|---|
| WHO Global Tuberculosis Report 2019 | View source |
Not provided
Accordance with EU General Data Protection Regulation and local data protection law needs to be worked out.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| D055985 | Latent Tuberculosis |
| D014397 | Tuberculosis, Pulmonary |
| D003141 | Communicable Diseases |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Urine, Serum, Plasma, Full blood, Peripheral blood mononuclear cells (PBMCs), Sputum
|
| Classification of cases of co-prevalent or incident TB; through M.tb isolate sequencing and comparison with the source case isolate |
Classification of cases of co-prevalent or incident TB; through M.tb isolate sequencing and comparison with the source case isolate:
|
| through study completion, up to Month 24 |
| Assessment of the proportion of HHC (without co-prevalent TB) with abnormal pulmonary function at baseline | to assess the proportion of HHC (without co-prevalent TB) with abnormal pulmonary function at baseline, the type and severity of impairments, the relationship between pre-existing abnormal pulmonary function and incident TB (and the changes in pulmonary function measured by spirometry after incident TB and TB treatment completion). | Spirometry will be done only at baseline |
| NIMR - Mbeya Medical Research Centre |
| Mbeya |
| Tanzania |
| Biomedical Research & Training Institute (BRTI) | Harare | Zimbabwe |
| Fox GJ, Nhung NV, Sy DN, Hoa NLP, Anh LTN, Anh NT, Hoa NB, Dung NH, Buu TN, Loi NT, Nhung LT, Hung NV, Lieu PT, Cuong NK, Cuong PD, Bestrashniy J, Britton WJ, Marks GB. Household-Contact Investigation for Detection of Tuberculosis in Vietnam. N Engl J Med. 2018 Jan 18;378(3):221-229. doi: 10.1056/NEJMoa1700209. |
| 30865794 | Background | Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. |
| 42026013 | Derived | Larsson L, Olaru ID, Behnke AL, Marambire ET, Chipinduro M, Calderwood CJ, Banze D, Mfinanga A, Nhamuave C, Mwambola HL, Held K, Gupta RK, Minja LT, Khosa C, Heinrich N, Kranzer K; ERASE-TB consortium. Diagnostic and prognostic accuracy of the Mycobacterium tuberculosis host response 3-gene cartridge among tuberculosis household contacts in Mozambique, Tanzania, and Zimbabwe: a prospective, longitudinal, diagnostic and prognostic accuracy cohort study. Lancet Infect Dis. 2026 Apr 20:S1473-3099(26)00114-3. doi: 10.1016/S1473-3099(26)00114-3. Online ahead of print. |
| 36427173 | Derived | Marambire ET, Banze D, Mfinanga A, Mutsvangwa J, Mbunda TD, Ntinginya NE, Celso K, Kallenius G, Calderwood CJ, Geldmacher C, Held K, Appalarowthu T, Riess F, Panzner U, Heinrich N, Kranzer K; ERASE-TB Consortium. Early risk assessment in paediatric and adult household contacts of confirmed tuberculosis cases by novel diagnostic tests (ERASE-TB): protocol for a prospective, non-interventional, longitudinal, multicountry cohort study. BMJ Open. 2022 Jul 19;12(7):e060985. doi: 10.1136/bmjopen-2022-060985. |
| Consensus Meeting Report: Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease | View source |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D000085343 | Latent Infection |
| D012141 | Respiratory Tract Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |